Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophos…
Biotechnology
GB, London [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -9.20 | 25.24 | 27.79 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 4.62 | 28.69 | 27.42 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | -2.27 | 7.43 | 7.61 | |
| Cash | -2.30 | 8.14 | 8.33 | |
| Capex | 1.97 | < 0.005 | < 0.005 | |
| Free Cash Flow | 48.53 | -0.14 | -0.26 | |
| Revenue | -22.33 | 0.04 | 0.05 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -5.96 | 0.85 | 0.90 | |
| Operating Margin | -93.25 | -9.19 | 136.27 | |
| ROA | -97.00 | -0.02 | 0.70 | |
| ROE | -96.97 | -0.03 | 0.84 | |
| ROIC | -94.86 | -0.04 | 0.76 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of ROIV is permitted for members.
5
Growth
The "Growth Entry" for the Focus of ROIV is permitted for members.
6
Leverage & Liquidity